Recursion Pharmaceuticals EBIT

The latest EBIT for RXRX is $-560M as of June 2026. That compares with $-640M in the prior-year period — up 12.5% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Recursion Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, RXRX's EBIT moved from $-640M to $-560M — a 12.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Recursion Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, RXRX currently prints $-560M for EBIT, while the sector average sits near $23B. That is roughly 102.4% below the sector mean. Large gaps often invite a closer look at Recursion Pharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-560M for RXRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting RXRX's EBIT ($-560M), review year-over-year change from $-640M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.